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Colorectal cancer (CRC) presents a considerable disease burden worldwide. The human colon is also
an anatomical location with the largest number of microbes. It is natural, therefore, to anticipate a role for
microbes, particularly bacteria, in colorectal carcinogenesis. The increasing accessibility of microbial
meta’omics is fueling a surge in our understanding of the role that microbes and the microbiota play in
CRC. In this review, we will discuss recent insights into contributions of the microbiota to CRC and explore
conceptual frameworks for evaluating the role of microbes in cancer causation. We also highlight new
findings on candidate CRC-potentiating species and current knowledge gaps. Finally, we explore the roles
of microbial metabolism as it relates to bile acids, xenobiotics, and diet in the etiology and therapeutics
of CRC.Introduction
The human large bowel is a common site for adenocarcinomas
and also one of the most densely populated microbial ecosys-
tems on our planet. Colorectal cancers (CRCs) affect over a
quarter of a million people each year. In industrialized nations,
the lifetime risk of developing CRC is approximately 5%, and
the lifetime risk of developing an adenoma, a noncancerous co-
lon tumor that can develop into CRC, is 20%. When the disease
is local or confined, cure rates range from 70%–90%; however,
advanced CRC has a high mortality rate, consistently ranking in
the top three causes of cancer-related death around the globe.
There has been long-standing curiosity about the role of bacteria
in colorectal carcinogenesis, because of the large disease
burden of CRC and the microbial load of the colon; and recent
heightened interest in the gut microbiome in CRC, because of
the increasing accessibility of microbial meta’omics.
Sequencing technologies have vastly expanded our under-
standing of the human genetic landscape of CRC. Similarly, ef-
forts at sequencing CRC microbiomes are providing leads into
how a microbe’s interactions with an individual’s entire colonic
microbial community, clades within that community, or the
human holobiont (Gordon et al., 2013), the entirety of the assem-
blage of both human and microbe, may be associated with colo-
rectal carcinogenesis. Studies of candidate species in model
systems have been useful in evaluating cancer causality and
are in keeping with reductionist scientific experimental para-
digms. However, an equally plausible concept is that consortia
of microbes contribute to CRC risk over time, which can be a
far more challenging concept to observationally or experimen-
tally interrogate. This concept is well-aligned with human ge-
netic-based models of colorectal carcinogenesis, namely that
molecular alterations in multiple genes underlie the developmentof a hyperplastic epithelium and propel progression onto ade-
noma and then toward adenocarcinoma. Mutations in human
genes that influence adenoma and adenocarcinoma develop-
ment may shape the growth rate of colonic epithelial cells
(CECs), reduce their susceptibility to cell death, endow them
with metabolic specializations, and confer on them abilities to
commandeer immune cells to further promote growth and
spread. Similarly, microbes can be viewed as collections of
gene networks that affect cancer genomic stability, metabolism,
and immune responsiveness. In turn, it is possible that the
characteristics of transformed CECs render themmore sensitive
to microbially influenced carcinogenesis.
Herein, we will discuss recent insights into contributions of
the microbiota to CRC. We explore conceptual frameworks for
evaluating the role of microbes in cancer causation as we high-
light new findings on candidate CRC-potentiating species and
knowledge gaps. We will not summarize howmicrobially elicited
inflammation or host microbial-sensing pathways affect carcino-
genesis, as these topics have been the subject of several recent
reviews (Dejea et al., 2013; Kostic et al., 2013a; Jobin, 2012;
Schwabe and Jobin, 2013; and see review in this issue of Cell
Host & Microbe by Goldszmid et al. [2014]). Instead, we concen-
trate on microbial metabolism in colorectal carcinogenesis with
a focus on bile acids and also touch upon xenobiotics and
food, all of which are areas where the microbiota has the poten-
tial to explicate observations about host gene-environmental
interactions in carcinogenesis.
Causality Theory
CRC is essentially a genetic disease (Figure 1). Gradual accumu-
lation of oncogenic gene mutations leads to autonomous CEC
proliferation that slowly progresses typically over 10–40 years,Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 317
Figure 1. Genetic Alterations and the Progression of CRC
The major signaling pathways that drive the development of CRC are shown at the transitions between each tumor stage. One of several driver genes in each
signaling pathway can be altered in an individual tumor. Patient age indicates the time interval during which the driver genes are usually mutated. The classic
‘‘Vogelgram’’ shown in the upper panel is adapted from Vogelstein et al. (2013). A map of genes mutated in CRC is shown in the lower panel, with peak height
indicating that a large percentage of human colorectal tumors harbor such mutations (adapted from Wood et al., 2007).
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viduals, cancers. Initiation of colon tumors (adenomas, adeno-
carcinomas) refers to events yielding biologic changes fostering
CEC proliferation; progression refers to the subsequent events
that liberate growth of the incipient colon tumor and, ultimately,
transformation to cancer. Yet, it remains unknown with any pre-
cision what events precipitate either the initial, disease-initiating
mutation(s) or foster the subsequent disease progression. The
microbiome, however, is a prime suspect for triggering the initi-
ation and/or progression of colonic carcinogenesis. Certainly,
in murine disease models, colon mucosal inflammation, often
induced by mucosal irritants (dextran sulfate sodium, 2,4,6-
trinitrobenzenesulfonic acid) combined with administration of a
carcinogen (often azoxymethane, a compound in engine fuel),
yields colon tumorigenesis, substantiating the intersection of
inflammation and exposure to carcinogens in colon tumorigen-
esis. Certain engineered murine gene knockouts, with potential
mucosal inflammation sequelae, also yield colon carcinogenesis
that is ameliorated in germ-free animals or sometimes merely by
a vivarium change, often considered a proxy for acquisition of a
new microbiota. While these models support the hypothesis
that the microbiota contributes to colon carcinogenesis, they
poorly mimic human disease development. Until recently, the
contribution of the human colon environment, home to the318 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.largest and most complex microbial mass of human ecology,
was not integral to the analytical framework of translational
CRC research.
What can guide us as we seek to determine if and how the
colon microbiome contributes to the pathogenesis of sporadic
human CRC? One clear limitation in seeking a microbe as the
cause of a chronic disease is the possibility that the inciting
microbe is no longer present at the time the disease is identified,
perhaps gradually eliminated by changes in tumor microenviron-
ment no longer hospitable to the microbe or, alternatively,
because the microbe acts by a ‘‘hit and run’’ mechanism
whereby limitedmicrobial exposure is sufficient to incite disease.
For example, in the case ofH. pylori and gastric cancer, isolation
of H. pylori declines with advancing gastric cancer, although
detection of H. pylori exposure is usually still possible by
serology (Ota et al., 1998). This reinforces the importance of
utilizing multiple approaches in seeking to link a microbe to
disease ‘‘causation.’’
Figure 2 provides a framework for considering the microbiota
and specific members of the microbiota as either primary
(initiators) or secondary (fostering progression) contributors to
human CRC pathogenesis (Sears and Pardoll, 2011). We
consider three models by which specific microbes (model 1),
a microbial community (model 2), or the two acting sequentially
Figure 2. Microbial Contributions to the Pathogenesis of Colorectal
Cancer
Complex host-microbiota interactions are considered probable primary or
secondary contributors to the pathogenesis of CRC. From the microbiota
perspective, several hypotheses are actively under investigation, including
disease instigation or promotion through individual microbes (model 1), the
collective microbiota (model 2), or an interactive model in which single mi-
crobes drive the emergence of a modified, disease-generating microbiota
(model 3). From the host perspective, the microbiota may alter tumor-asso-
ciated inflammation with consequences for tumor biology, or conversely, the
tumor microenvironment or associated inflammation may induce microbiota
shifts with the potential to further inhibit or promote tumor biology. Host
genetic polymorphisms that modify immune and metabolic responses are
predicted to play a key role in host-microbiota interactions during colonic
carcinogenesis. See text for details.
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With respect to the first model, we well understand that individ-
ual microbes such as the pneumococcus, the meningococcus,
Helicobacter pylori, or hepatitis viruses are established etiol-
ogies of host pathology. We consider that these microbial path-
ogens possess sufficient virulence mechanisms enabling them
to act alone in disease causation. In contrast, as a secondmodel,
inflammatory bowel disease stands as the best prototype for
microbial community disease causation (Sears and Pardoll,
2011). In this disease, host genetics is the presumed initiator
permissive to development of a dysbiotic (implying dysfunc-
tional, disease-initiating or -amplifying) microbiome with an
ensuing cycle of host gene-microbiota interactions causing in-
testinal and possibly extraintestinal disease. Experimental
work definitively supports this pathogenetic sequence in that
dysbiotic colonic microbiota develop in at least select mice
with gene knockouts (e.g., Tlr5, Il10, T-bet, and Rag2) and that
this emergent dysbiotic microbiome alone possesses the capac-
ity to transmit to a healthy mouse (without any gene mutations)
the disease of interest (Garrett et al., 2007, 2010; Vijay-Kumar
et al., 2010). Importantly, these murine experiments strongly
support the idea that the dysbiotic microbiota can, as a commu-
nity, encode tissue-specific (e.g., colitis) as well as systemic
disease (e.g., metabolic syndrome, obesity) (Ridaura et al.,
2013; Vijay-Kumar et al., 2010).
Human CRC provides an opportunity to consider individually
the above disease causation scenarios as well as a novel hy-
pothesis in which these theories blend with individual or limitedbacterial species acting in concert with a locally modified micro-
biome to cause CRC (Figure 2, model 3). Nuances of a limited
microbial consortium inducing colon tumorigenesis include the
possibilities of sequential microbial exposure or polymicrobial
disease causation. For this third disease model, we lack clear,
clinically relevant historical examples to guide us except for the
requirement of the hepatitis B virus for replication and disease
induction by the hepatitis D virus. For example, while we under-
stand that the pneumococcus or the meningococcus invades
the host from among a complex microbiota in the respiratory
tree or nasopharynx, we have no clear data suggesting that the
composition of these microbial communities is required for or
contributes to the disease causation potential of these bacteria.
Similarly, the intestinal microbiota has been shown to hinder or
exacerbate viral infections in murine models, but the responsible
bacteria are not known (Wilks et al., 2013).
It will not be easy to discern among these potential disease
models that provide a framework for defining the microbe con-
tributions to human CRC pathogenesis. Carefully designed
studies that consider the Bradford Hill criteria (Bradford Hill,
1965) are needed to link the microbiota and/or select microbes
with CRC initiation and progression. A view from the colon lumen
may be insufficient. Rather, microbial datamust be considered in
the context of key host parameters such as the host immuno-
logic response (including the tumor microenvironment) and
host gene polymorphisms that influence the host immune
response as well as host susceptibility to CEC gene mutations.
The Microbiome Community as Protagonist
The seminal work of Eckburg et al. clarified the complexity of
the fecal and mucosal colon microbiota, importantly illustrating
two key points relevant to the colon microbiome as causal in
colonic carcinogenesis (Eckburg et al., 2005). First, the majority
of microbes, predominantly bacteria, within the colon microbial
community are ‘‘noncultivatible.’’ While this concept has been
challenged by subsequent work, it remains clear that a complete
cultured or genome sequence catalog of the colon microbiome
with strain-level resolution is still far from our reach (Lagier
et al., 2012). Thus, at this time, associations between the micro-
biota and CRC rely on approaches to broadly define the compo-
sition or function of the colon microbiome using various ‘‘omic’’
approaches (16S rRNA gene sequencing, metagenomics, tran-
scriptomics, proteomics, metabolomics). Second, while the
colon mucosal community may not vary substantially along the
axis of the colon, the mucosa-associated community differs
from the intraluminal microbiome. These data raise the important
and yet unanswered question of whether the fecal microbiome
alone will sufficiently mirror mucosal events to allow ‘‘causation’’
to be established.
The data set to address microbial community associations in
human CRC is limited and has focused on defining bacterial
communities associated with colon tumorigenesis. The available
studies yield several worthy, albeit preliminary, observations
(Dejea et al., 2013). First, the bacterial community composition
in colon adenoma or CRC patients, both in mucosal samples
and feces, differs from the examined control samples, although
consistent associations of bacterial groups with tumor samples
or tumor hosts is not yet discernible. Second, ‘‘on-tumor’’ and
‘‘off-tumor’’ mucosa bacterial populations differ within the tumorCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 319
Table 1. Criteria for Disease Causation: Human Colorectal
Cancer and Putative Bacterial Protagonists
Criteriaa S. gallolyticus ETBF E. faecalis E. coli F. nucleatum








 + + +e +
Biological
plausabilityf





    
Presence or absence of data is noted by + (present) or – (absent); ± de-
notes overall data are variable.
aAdapted from Evans (1976) and Fredericks and Relman (1996).
bEpidemiology encompasses several types of evidence, including pre-
valence, exposure, or incidence of disease significantly higher in those
exposed to the putative cause than controls; data comparing cases
and controls should show consistency and strength of association;
a range of controls should be evaluated to assess specificity of the
epidemiologic association; temporality (exposure antedates disease
development).
cOnly data assessing human immunologic responses are considered.
dExperimental disease induction refers to animal models demonstrating
increased colon carcinogenesis by the listed bacterium.
eExperimental model data are only available for E. coli possessing the
pks island.
fBiologic plausibility reflects the authors’ judgment of the strength of
the data available at present regarding the potential role of the bacterial
protagonist in human CRCs.
gElimination or modification of agent prevents disease refers to human
studies such as use of antibiotics, probiotics, or vaccines to prevent dis-
ease. As yet, no such studies are reported for these bacteria and CRC.
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samples differ consistent with prior studies in healthy individuals.
Lastly, while considerable study-to-study differences in de-
tected bacterial groups by sample are reported (including nearly
polar opposite findings), studies have identified enrichment of
Fusobacterium spp. (most often identified as F. nucleatum) asso-
ciated with CRC mucosa compared to nontumor, histologically
normal colon tissues from the same cancer-bearing host (Castel-
larin et al., 2012; Kostic et al., 2012). Additional work has further
identified enrichment of Fusobacterium spp. in fecal samples
from CRC hosts compared to healthy individuals (Ahn et al.,
2013; Kostic et al., 2013b). These observations are discussed
in more detail below. Several of the available colon tumor micro-
biome studies have limitations, including small sample sizes,
undefined tissue sampling sites, limited or absence of control
samples (including healthy controls and/or control tissues within
the tumor host), limited or no metadata (subject clinical data,
e.g., patient age, family history, past medical history, current
and past medications, dietary patterns, cancer stage, or tumor
KRAS, PIK3CA, BRAF, NRAS mutational status), and/or poorly
described analyses. Differing study designs, including types of320 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.samples analyzed and populations included combined with, for
example, unknown dietary habits or other risk factors for CRC
that are associated in other data sets with modified colon micro-
biomes, make it difficult to glean themes across these studies.
When considered within the Bradford Hill framework for esta-
blishing causality, our knowledge of the community microbial
associations in CRC remains quite limited. For example, as yet
no study has examined in parallel fecal and mucosal samples
from nontumor hosts compared to the fecal and mucosal com-
munities present in colon tumor hosts (‘‘on-tumor’’ and ‘‘off-
tumor’’). This approach might help us discern specific microbial
associations and could provide the basis for prospective testing
for disease identification. Prospective, longitudinal study of
individuals at high risk for development of CRC will need to be
done to discern if shifts of the colon microbiome occur coinci-
dent with disease development consistent with the epidemio-
logic principle that exposure must antecede disease expression.
Also outstanding are serologic, proteomic, and metabolomic
studies of human CRC and controls to identify potential fecal,
mucosal, or serum colon tumor-specific molecular markers for
disease prediction that might simplify screening for this highly
preventable disease. Further, although the right and left colonic
mucosal communities appear similar in the healthy host, the
molecular features of right and left CRC can differ (Yamauchi
et al., 2012), raising the question of whether regional microbial
associations may distinctly affect the genesis of colon tumors,
a point not yet addressed by available data. Lastly, there is
uncertainty about the population sizes required to identify the
‘‘correct’’ causal associations, if these exist. For example, the
population size to detect a single microbe as causal will likely
be much smaller than if a particular community exposure or
polymicrobial, even sequential, exposure is critical. Certainly,
large populations were necessary to identify the effect of
KRAS mutations, aspirin, or diet on colorectal carcinogenesis.
Individual Microbes as Protagonists
There is a long history of attempting to associate individual
microbes, mostly bacteria, with human CRC (Aries et al., 1969;
Hill et al., 1971). As examples to guide our thinking, herein we
discuss data on select bacteria that may serve as protagonists
of human CRC. Table 1 summarizes how the data on colon
carcinogenesis promoted by these individual bacteria align
with criteria supportive of disease causality as classified by
Evans (1976) and Fredericks and Relman (1996).
Streptococcus gallolyticus
Identification of S. gallolyticus subspecies gallolyticus (the
former S. bovis, biotype 1) in the bloodstream has been a strong
and consistent predictor of colon pathology, often colon ade-
nomas or cancers, for nearly 40 years (Boleij and Tjalsma,
2013; Boleij et al., 2011b). In fact, positive blood cultures for
S. gallolyticus mandate clinical examination of the colon
for pathology. While co-occurrence of colon neoplasia with
S. gallolyticus bloodstream infection is infrequent, estimated
at less than 1%, molecular approaches have detected
S. gallolyticus DNA in 20%–50% of colon tumor or nontumor
colon mucosal tissues from tumor hosts compared to <5% of
control tissues (Abdulamir et al., 2010). Despite evidence of
S. gallolyticus colonization in colon tumor hosts, it is uncertain
whether S. gallolyticus is mere opportunist invader in the setting
Cell Host & Microbe
Reviewof a breach in the colon mucosal barrier or if it contributes,
through specific virulence mechanisms, to transformation in
the colon. S. gallolyticus, compared to other members of the
S. bovis complex, possesses a pilus protein (encoded by the
pil1 locus) with a collagen-binding domain, exhibits a growth
advantage under metabolic conditions associated with colon tu-
mors, can translocate efficiently through a paracellular epithelial
route, or is associated with enhanced inflammatory signals
including Ptgs2 (COX-2) (Abdulamir et al., 2010; Boleij et al.,
2012, 2011a). These observations suggest that S. gallolyticus
is poised to colonize and invade colon tumors and may enhance
tumor growth through inflammatory signals. In vivo detection
studies as above and serologic assays suggest that exposure
to S. gallolyticus does not characterize the majority of individuals
with CRC (Boleij and Tjalsma, 2013). Thus, the S. gallolyticus
contribution to the pathogenesis of human CRC is likely
restricted to a subset of individuals, in whom it may enhance
tumor growth.
Enterococcus faecalis
E. faecalis strains differ in their capacity to produce reactive
oxygen species capable of inducing DNA damage and genomic
instability, and those E. faecalis strains producing extracellular
superoxide anions have been proposed as initiators of CRC.
Experimental studies using an oral symbiotic E. faecalis strain
suggest that E. faecalis-triggered carcinogenesis is mediated
by inducing mucosal macrophages to produce diffusible clasto-
gens (chromosomal-breaking factors) such as 4-hydroxy-2-
nonenal (a breakdown product of u-6 polyunsatured fatty acids)
that mediate DNA damage through a bystander effect (Wang
et al., 2008, 2012; Yang et al., 2013). The potential oncogenicity
of certain E. faecalis strains is further supported by observations
that superoxide-producing E. faecalis induce marked distal coli-
tis, DNA damage, and cancer in germ-free Il10/mice, whereas
superoxide-deficient E. faecalis induce inflammation but not
tumor formation (Wang et al., 2012). Human data testing these
concepts are limited to a prospective case cohort study of
consecutive colonoscopy patients in which fecal E. faecalis
populations were identified as unstable over >1 year and an
association of superoxide-producing E. faecalis with detection
of large colon adenomas or cancer was not found (Winters
et al., 1998).
Enterotoxigenic Bacteroides fragilis
Enterotoxigenic Bacteroides fragilis (ETBF), a cause of human
diarrheal illnesses, was initially proposed as a potential microbial
instigator of human CRC based on studies of the mechanism
of action of the organism’s only recognized virulence factor,
the B. fragilis toxin (BFT; also known as fragilysin). BFT, a zinc-
dependent metalloprotease toxin, rapidly alters CEC structure
and function, including cleavage of the tumor suppressor pro-
tein, E-cadherin, resulting in enhanced nuclear Wnt/b-catenin
signaling that yields increased colonic carcinoma cell prolife-
ration and expression of the protooncogene, MYC. Loss of
E-cadherin increases the permeability of polarized CEC mono-
layers, and an increase in colonic permeability prior to tumor
development is an early pathophysiologic change associated
with incipient CRC (Soler et al., 1999). BFT also triggers NF-kB
signaling that induces CEC secretion of cytokines that likely
contribute to the development of mucosal inflammation; further
NF-kB signaling may contribute to CEC carcinogenesis. Collec-tively, these in vitro studies of the mechanism of action of BFT
suggested the toxin, and hence the organism,may be oncogenic
(Sears, 2009).
This hypothesis was tested using multiple intestinal neoplasia
(ApcMin/+) mice that are heterozygous for the Apc gene and
considered a classic model for CRC pathogenesis given that
Apc mutations are present in most human CRCs. In ApcMin/+
mice, persistent colonization with ETBF (a piglet isolate)
markedly and rapidly increased colon adenoma formation
(Wu et al., 2009). ETBF both accelerated the time course and
altered the distribution of colon tumor formation in ApcMin/+
mice. By histology, colon microadenomas were detectable as
early as 1–2 weeks after colonization and visible colon tumors
by 1 month postcolonization, a time line that is markedly accel-
erated compared to ApcMin/+ mice not colonized with ETBF.
Further, the majority of adenomas in ApcMin/+ mice are detected
in the small bowel, with limited adenoma formation scattered
through the colon. Upon ETBF colonization, distal colon tumor-
igenesis, but not small bowel adenoma formation, is augmented.
Mechanistically, specific Stat3 activation with induction of a
mucosal IL17 response was shown to mediate, at least in part,
ETBF colon carcinogenesis, the first demonstration of the contri-
bution of Th17 adaptive immune responses to carcinogenesis.
Subsequently, development of an IL17 immune response was
linked to a worse prognosis in human CRC (Tosolini et al.,
2011). ETBF in vivo and BFT in vitro also induce DNA damage
in CECs (Goodwin et al., 2011). Thus, the in vitro and in vivo
biologic basis for considering ETBF as a potential contributor
to colon carcinogenesis is strong.
In contrast, human data to directly link ETBF to CRC are
currently limited, although the framework for considering ETBF
as an instigator of CRC is more promising. Exposure to ETBF
begins in early childhood, where this bacterium was first asso-
ciated with human diarrheal disease, and ETBF acquisition ap-
pears to be relatively common, at least in some locales (Sears,
2009). Subsequent data suggest that asymptomatic adult
colonization with ETBF is also common, occurring in up to
40% of individuals (Zitomersky et al., 2011). However, whether
ETBF is a persistent colon colonizer throughout life and/or is
associated with subclinical, potentially CRC-promoting, colonic
inflammation in humans remains unknown. Consistent with this
idea, a persistent, subclinical IL17-dominant colitis is identified
in mice with long-term ETBF colonization (Wick et al., 2014).
Further, chronic ETBF colonization is associated with subclini-
cal, inflammatory foci in which coincident Stat3 activation in in-
flammatory cells and overlying CECs occurs. These murine
data suggest that long-term ETBF colonization may yield foci
at risk for CEC transformation. Overall, the data suggest that
ETBF may exhibit the correct temporal relationship for consider-
ation as an instigator of CRC, a disease estimated to require
10–40 years from inception to clinical detection. A single study
from Turkey has examined ETBF in a CRC population so far
(Toprak et al., 2006). Using bft as themarker, ETBFwas detected
significantly more often in the stools of consecutive cases
of CRC compared to concurrent hospital-based, age- and
gender-matched patients without CRC (38% ETBF in 73 cases
of CRC, and 12% ETBF in 59 controls, p < 0.01). Importantly,
B. fragilis was isolated in similar percentages of both CRC cases
and controls. Together in vitro and in vivo experimental modelsCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 321
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promote colon carcinogenesis.
Escherichia coli
One of the earliest studies to employ molecular methods to
examine the microbiota of adenomas, CRCs, and healthy colo-
noscopy control biopsies identified the versatile E. coli as dispro-
portionately associated with tumor samples. Using the classic
gentamicin protection assay, intracellular E. coli could be recov-
ered from 81% of 16 colon tumor (adenoma or cancer) samples
examined compared to none of 25 control biopsies (Swidsinski
et al., 1998). Subsequently, two groups of E. coli have been of
particular interest with respect to the pathogenesis of CRC,
genotoxic E. coli, and tightly adherent E. coli. Among potential
genotoxic E. coli, phylogenetic group B2 E. coli induces dou-
ble-strand DNA breaks through the polyketide synthase (pks)
island containing the genotoxin colibactin (Cuevas-Ramos
et al., 2010; Nougayre`de et al., 2006). The concept that E. coli
through the pks island and colibactin promotes colon carcino-
genesis was strengthened by data revealing that deletion
of the pks island reduced DNA damage, tumor numbers, and
bacterial invasion, but not inflammation, in a murine colonic
oncogenesis model (Il10/ mice treated with azoxymethane)
colonized with a murine E. coli strain possessing the pks island
(Arthur et al., 2012). Thus, carcinogenesis in this model required
inflammation plus a specific bacterial virulence factor, a concept
further enhanced by observations that a strain of E. faecalis
also induced inflammation but not colon tumorigenesis in this
murine model. However, other data indicate that the type of
inflammation is critical in facilitating carcinogenic biologic
events, with Th1 and Th17 inflammatory responses generally
being anti- and procarcinogenic, respectively (Yu et al., 2007).
The character of the colonic inflammation induced by E. coli
possessing or not the pks island was not determined in this
model, and thus it is possible that deletion of the pks island re-
sulted in a shift in the inflammatory environment from procarci-
nogenic to anticarcinogenic. Limited human data suggest that
colibactin-positive E. coli are more common in CRC and inflam-
matory bowel disease patients and even are identified in fecal
samples from infants where persistent colonization, at least to
18 months of age, is frequent (Arthur et al., 2012; Buc et al.,
2013; Nowrouzian and Oswald, 2012). Other E. coli with defined
(e.g., cytotoxic necrotizing factor or cytolethal distending toxin)
or undefined genotoxic factors have also been isolated from
the colonic mucosa, although there are little data on their asso-
ciations with human CRC (Buc et al., 2013). Enteropathogenic
E. coli (EPEC) that exhibit characteristic tight intestinal epithelial
cell adherence (also known as attaching and effacing lesions)
and are well-known as a common cause of acute and persistent
diarrhea in children have also been proposed as potentially
carcinogenic via downregulation of DNA mismatch repair pro-
teins (Maddocks et al., 2009). EPEC were detected in 25% of
20 formalin-fixed adenocarcinoma tissues, but not in normal
colon tissues from the same individuals. Overall, E. coli possess-
ing the pks island are the current strongest E. coli candidate
for being a contributor to colon carcinogenesis.
Fusobacterium spp.
Fusobacterium spp. initially arose as potential bacteria contri-
buting to the pathogenesis of CRC through complementary
unsupervised genomic methods analyzing the microbial associ-322 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.ations of CRCs versus matched normal tissues from the same
host. Metagenomic, 16S rDNA, and RNA-sequence analyses
supported an enrichment of Fusobacterium sequences associ-
ated with tumor samples relative to the normal colon tissue
from the same cancer-bearing host (Castellarin et al., 2012; Kos-
tic et al., 2012). The results were further supported by visualiza-
tion of excess Fusobacterium by fluorescent in situ hybridization
(FISH) on tumors compared to parallel host normal colon tissue
and quantitative PCR (qPCR). F. nucleatum appeared to be the
dominant phylotype, although multiple species were detected.
A single cancer-associated F. nucleatum isolate was invasive
in tissue culture, consistent with the known clinical spectrum
of fusobacteria that act as invasive anaerobes in oral and
endometrial infections as well as appendicitis and inflammatory
bowel disease (Castellarin et al., 2012; Strauss et al., 2011).
Subsequent work further confirmed the tumor association of
Fusobacterium spp. as well as identified fusobacteria as more
abundant in the normal rectal mucosa of adenoma patients
compared to nonadenoma controls, more abundant in adenoma
tissue than in patient-matched normal colon tissues, and more
abundant by qPCR in the stool of patients with adenomas or
adenocarcinomas compared to the stools of healthy individuals
without colon tumors (Ahn et al., 2013; Kostic et al., 2013b;
McCoy et al., 2013; Warren et al., 2013). Although Fusobacte-
rium was not associated with particular tumor characteristics,
it was more abundant on colon tumors from Spain when
compared to tumors from the United States and Vietnam. This
suggests that Fusobacterium colonization may vary regionally,
although the reasons for this, such as diet, for example, are
unknown (Kostic et al., 2012).
Recent data provide experimental support for a tumor-induc-
ing role of F. nucleatum. Chronic exposure of ApcMin/+ mice to
a F. nucleatum strain isolated from an inflammatory bowel
disease patient induced a modest, but significant, increase in
colon adenomas as well as small bowel tumors. Again excess
F. nucleatum was detected on the tumor compared to normal
murine colonic tissues (Kostic et al., 2013b). In contrast to
most murine models of intestinal carcinogenesis, mucosal
inflammation was not detected in nontumorous colon tissue
of the F. nucleatum-infected ApcMin/+ mouse. However,
F. nucleatum induced an expansion of myeloid-derived immune
cells in the tumor microenvironment of small bowel tumors as
well as upregulated inflammatory genes in both small intestinal
and colon tumors. These results were further supported by
a correlation between the abundance of Fusobacterium, but
not other bacterial genera, and NF-kB p65 nuclear translocation
as well as expression of myeloid-associated and NF-kB-driven
inflammatory genes in human CRCs.
In experimental work using a periodontal disease-derived
F. nucleatum strain, the invasive and carcinogenic properties
of F. nucleatumwere suggested to be mediated by the activated
complex of the FadA adhesin (FadAc) of F. nucleatum (Rubin-
stein et al., 2013). In vitro colon carcinoma cell line studies and
tumor xenograft models revealed that FadAc binds to a select
extracellular domain of E-cadherin triggering invasion of the
organism as well as activation of b-catenin/Wnt signaling with
stimulation of cell proliferation or tumor growth, respectively.
Of note, E-cadherin binding appeared to be sufficient to
trigger b-catenin/Wnt signaling with oncogene transcription,
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additional NF-kB signaling. Evaluations of tumor tissues from
adenoma and adenocarcinoma patients compared to normal
colon tissue from nontumorous individuals revealed fadA gene
copy number was elevated in tumor tissues. The highest fadA
gene copies were detected in cancer tissues in association
with increased fadA transcripts and concomitant increases in
expression of representative Wnt and NF-kB genes, consistent
with the results of in vitro FadAc studies.
Collectively, F. nucleatum and possibly other Fusobacterium
spp. are more abundant in some CRC-bearing hosts, found
particularly in association with tumor tissues, and experimental
data provide support for carcinogenesis being mediated
through Wnt signaling with coincident skewing toward
myeloid-derived and NF-kB inflammation in the tumor micro-
environment. The data also reveal that there is a gradient in
the fecal abundance of F. nucleatum across healthy and
tumor hosts, suggesting that Fusobacterium detection, in and
of itself, may not be a sufficiently robust biomarker for identi-
fying patients at increased risk for colon tumors (Kostic et al.,
2013b). Similarly, and consistent with data on other individual
bacterial CRC protagonists, only a subset of tumors display
enhanced abundance of Fusobacterium, and the relative
abundance differs markedly between tumors (e.g., 2-fold to
>10,000-fold compared to normal tissues within the tumor
host; Castellarin et al., 2012). Data to support a correlation
between Fusobacterium abundance and tumor oncogenic
properties or disease stage remain outstanding. The epidemi-
ology of acquisition or colonic colonization of Fusobacterium
spp. is also unknown. In particular, whether the oral fusobac-
teria commonly associated with periodontal disease are in
fact related to the Fusobacterium spp. detected in the colon
requires further investigation.
Overall, two common themes emerge regarding the mecha-
nisms by which individual bacteria may contribute to human
CRC pathogenesis. The first theme, based on studies on
ETBF, E. faecalis, E. coli, and F. nucleatum, suggests that
members of the colonic microbial community capable of trig-
gering Wnt signaling and/or select types of inflammation may
be human CRC protagonists. This concept is further supported
by the near-universal detection of gene mutations promoting
Wnt signaling in human CRC and our understanding that
all CRC exhibits enhanced inflammatory tone with evolving
human data suggesting that the features of this inflammatory
response are linked to disease prognosis. The second theme
supported by data on ETBF, E. faecalis, and E. coli is that
bacterial members of the colon microbiota capable of inducing
DNA damage and/or of interfering with DNA repair processes
may be critical to tumor initiation in the colon. Further, it is
easy to speculate, based on an understanding of bacterial
pathogenesis, that the capacity to breach the colonic mucus
layer and persistently adhere to the colonic mucosa is neces-
sary for members of the microbiota to initiate oncogenic
CEC signaling and/or to deliver specific oncogenic virulence
proteins or molecules in the colon. In this context, the early
CEC barrier changes associated with CRC (Soler et al., 1999;
Grivennikov et al., 2012) likely enhance the uptake of bacterial
molecules contributing to inflammatory signals and colon
carcinogenesis.A Consortium as Protagonist
The concept of a keystone species was introduced into environ-
mental science in 1969 and is defined as a species that plays
a critical role in maintaining the structure of an ecological
community and whose impact on the community is greater
than would be expected based on its relative abundance or total
biomass (http://www.washington.edu/research/pathbreakers/
1969g.html). Consistent with this idea, a number of studies
seeking to catalog and categorize the complex microbiota of
humans have suggested that minority microbiota members
may be prime contributors to microbiota function; in some
cases, single species or a limited set of species may serve to
distinguish the populations under study (Arumugam et al.,
2011; Koren et al., 2013; Qin et al., 2012). Further, the field of
microbial communication through quorum sensing and secretion
of hormones or antibacterial factors such as bacteriocins
strongly suggests that individual bacteria possess the capacity
tomodify, if not commandeer, their nearbymicrobial community.
Given these data and the complexity of the colonic microbiota,
the concept of a microbial leader that recruits a consortium of
disease-facilitating microbes to initiate the biologic events
causing CRC is appealing (Hajishengallis et al., 2012; Sears
and Pardoll, 2011; Tjalsma et al., 2012). After all, given the
complexity of the colonic microbiota, could all but one microbe
simply be passengers not contributing to disease development?
Despite its appeal, as yet no study has specifically tested this
idea in the causation of CRC, and thus this is an area where
carefully designed experimental work might help further our
concepts of how the microbiota contribute to the pathogenesis
of colon carcinogenesis.
Over the decades it takes for human CRCs to develop, several
microbial actorsmay be primary or secondary contributors. Their
biomolecular activities in relation to host physiology and in
response to a host’s diet or ingested pharmaceuticals may be
the factors that explicate environment and human gene interac-
tions in cancer causation and offer up new cancer biomarkers
and therapeutic targets. While well-designed microbial discov-
ery efforts are still warranted in human CRC, preclinical models
and other approaches which consider the contribution of
microbial metabolism to cancer prevention, development, and
treatment merit further investigation. Given our evolving under-
standing of the microbiome, longstanding clinical observations,
such as the connections between bile acids or dietary compo-
nents and gastrointestinal cancers, should be reconsidered
with a fresh perspective. With this in mind, we will explore
select aspects of microbial metabolism in colorectal carcino-
genesis and treatment that are more speculative in terms of their
mechanistic roles but represent areaswarranting re-examination
and further investigation.
High-Fat Diet and CRC: A Microbial Link?
Diets rich in saturated fats increase bile acid production, and
numerous studies have identified associations between diets
high in saturated fats and CRC (Williams et al., 2010; Reddy
2002). Gut bacteria are important contributors to bile acid meta-
bolism and thus may play a role in the biology linking bile acids
to CRC. As illustrated in Figure 3, there is significant interplay
between host and microbe in bile acid metabolism. The liver
secretes glycine and taurine conjugates of two bile acids, cholicCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 323
Figure 3. Host and Microbial Metabolism Affect CRC Risk
Host and microbiota cometabolism influence colonic bile pool exposure, drug
metabolism, and the breakdown of ingested foodstuffs with significant con-
sequences for CRC. The enterohepatic circulation of bile acids is shown from
the generation of the primary bile acids from cholesterol in the liver to the
generation of secondary bile acids by the intestinal microbiota. Bile acids
linked to decreased or increased CRC risk are highlighted. Both the liver and
the gut microbiota play critical roles in drug metabolism, with significant
effects on drug toxicity and response in CRC. Specific dietary components
have been implicated in increasing or decreasing CRC risk, e.g., saturated
fats, red and processed meats, and polyphenols. An individual’s gut microbial
metabolism may play a role in the beneficial or detrimental effects of certain
foods.
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deconjugated by bacteria to produce the secondary bile acids,
lithocholic and deoxycholic acid, the two dominant fecal bile
acids.
Both deoxycholic acid and lithocholic acid may contribute to
carcinogenesis. In studies of dietary fat intake and CRC risk,
elevated fecal lithocholic and deoxycholic acid have been found
in CRC patients relative to healthy controls (Gill and Rowland,
2002). Vancomycin-based perturbations of the gut microbiota
support the notion that bacteria are key drivers of high-fat-
diet-mediated increases in deoxycholic acid in mice (Yoshimoto
et al., 2013). In classic mutagenesis tests, like the Ames test,
both lithocholic acid and deoxycholic acid function can enhance
mutagenesis (Kawalek et al., 1983; Shibuya et al., 1997). In
rodent models of colorectal carcinogenesis employing chemical
carcinogens, deoxycholic acid and lithocholic acid potentiated324 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.tumor number and invasivity when their endogenous levels
were altered by surgery, by high-fat diet, or by delivery of
supraphysiologic doses to the gastrointestinal tract (Reddy,
1975; Summerton et al., 1985). Focusing on carcinogen-induced
liver cancer in mice, Yoshimoto et al. (2013) found that a high-fat
diet or genetic susceptibility to obesity resulted in deoxycholic
acid-mediated induction of the senescence-associated
secretory phenotype (secretion of proinflammatory and tumor
permissive factors by fibroblast-type cells) in hepatic stellate
cells and potentiated the development of liver cancer. Notably,
perturbing gut bacterial-mediated deoxycholic acid production
was sufficient to blunt the development of liver cancer in this
model.
Numerous mechanisms underpinning lithocholic and deoxy-
cholic role in carcinogenesis are likely at play. Both lithocholic
and deoxycholic acid can be proinflammatory in that they can
elicit reactive oxygen and nitrogen species production and
NF-kB activation in intestinal epithelial cells (Da Silva et al.,
2012; Lee et al., 2004; Mu¨hlbauer et al., 2004; Payne et al.,
2007). Chronic exposure to deoxycholic acid in vitro results in
DNA adducts as well as enhanced epithelial cell proliferation
and decreased apoptosis (Barrasa et al., 2013). Thus, lithocholic
and deoxycholic acid may represent procarcinogenic bacterial
metabolites and promising therapeutic targets.
Devkota et al. identified a mechanism that may explain the
observations about diets high in saturated fats and escalations
in inflammatory diseases in industrialized nations (Devkota
et al., 2012). Using Il10/ mice, the investigators found that
a diet enriched in milk-derived saturated fat versus polyunsatu-
rated-fat altered the composition and function of the gut
microbiota. A milk fat-enriched diet enhanced taurine (2-amino-
ethanesulfonic acid) conjugation of primary bile acids and re-
sulted in a bloom of the sulfur-reducing bacterium Bilophila
wadsworthia, which in turn exacerbated colitis in inflammation-
prone Il10/ mice. A recent human feeding intervention study
also supports that a high-fat diet may result in blooms in
B. wadsworthia (David et al., 2014). Examining the intersections
between dietary fat intake, gut microbiota composition and
function, and both primary and secondary bile acids may hold
promise not only for mitigating inflammatory disease like colitis
but also for attenuating the smoldering inflammation that con-
tributes to sporadic CRC.
Beyond dietary modification, there are other aspects of bile
acid microbial metabolism that may offer opportunities for can-
cer prevention. In contrast to lithocholic and deoxycholic acid,
ursodeoxycholic acid has a promising safety and health benefit
profile in humans and CRC preclinical models. Two enzymes,
a-hydroxysteroid dehydrogenase and 7b-hydroxysteroid dehy-
drogenase, catalyze the transformation of chenodeoxycholic
acid to ursodeoxycholic acid. In vitromany human intestinal bac-
teria, including Clostridium, Ruminococcus, and Eubacterium
strains, can convert chenodeoxycholic acid to ursodeoxycholic
acid. However, it is important that a given strain not also express
7b-dehydroxylase, which would convert the ursodeoxycholic
acid to the potentially toxic lithocholic acid. Ursodeoxycholic
acid is an approved therapy for primary biliary cirrhosis and is
generally well-tolerated. A few small, retrospective studies
examined if ursodeocycholic acid was useful for CRC prevention
in patients with a history of adenomas and inflammatory bowel
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powered to demonstrate efficacy (Carey and Lindor, 2012;
Serfaty, 2012). Screening, selection, and identification of human
intestinal bacteria that can generate ursodeoxycholic acid from
chenodeoxycholate in the small intestine could represent a
microbe-based approach for optimizing bile acid metabolism
for CRC prevention (Lepercq et al., 2004).
Xenobiotic Metabolism, the Gut Microbiota,
and Colon Cancer
Many compounds from pharmaceuticals to chemical carcino-
gens, collectively referred to as xenobiotics, are metabolized in
the liver and undergo further metabolism by the gut microbiota
(see Figure 3). The liver tends to engage in metabolism via oxida-
tion and conjugation reactions, while the gut microbiota favor
reduction and hydrolytic processes (Sousa et al., 2008). In the
liver some compounds are conjugated to glucuronic acid, which
makes them more water soluble and facilitates their excretion
in the urine and feces. Colonic bacterial b-glucuronidases can
hydrolyze these conjugates, resulting in their release within the
colonic lumen. This joint host and microbe cometabolism is
necessary for the chemical carcinogen azoxymethane to induce
intestinal tumors in mice (Fiala, 1977; Takada et al., 1982) and
can also contribute to the toxicity of many over-the-counter
and prescription drugs (Saitta et al., 2014).
Irinotecan, a commonly used intravenously delivered CRC
chemotherapy, is a topoisomerase-1 inhibitor. Like many che-
motherapies, irinotecan can cause both immune suppression
and diarrhea. However, in some patients, irinotecan can cause
a severe and refractory diarrhea that requires hospitalization
and limits the drug’s subsequent dosing and usage. Irinotecan
is a prodrug, and carboxylesterases, present in the serum and
throughout the body, convert it to SN-38. SN-38 is a topoisom-
erase-1 inhibitor 1,000 times more potent that irinotecan, and
it is glucuronidated in the liver (Kawato et al., 1991). However,
within the intestinal lumen, bacterial b-glucuronidase can
liberate SN-38 (Roberts et al., 2013). Thus the levels of intestinal
bacterial b-glucuronidase and subsequent degree of intestinal
epithelial SN-38 exposure influence the drug toxicity for patients.
In an elegant study, the Redinbo laboratory identified a potent
b-glucuronidase inhibitor that alleviated irinotecan toxicity in
mice (Wallace et al., 2010), and in subsequent studies they
have identified a number of compounds that are both microbially
selective and have EC50s in the nanomolar range (Roberts et al.,
2013). The identification of compounds that can improve drug
efficacy and reduce toxicity represents an exciting direction for
microbiota-based oncology therapeutics.
The gut microbiota may also contribute to chemotherapy
responsiveness via its influence on immune system function.
Recently Goldszmid et al. examined how oxaliplatinum, a drug
used to treat CRC, depends on the gut microbiota-immune sys-
tem interactions for the host to reap full benefits of its anticancer
effects (Iida et al., 2013; Goldszmid et al., 2014). While chronic
exposure to reactive oxygen species can increase the risk of
developing CRCs, tumor exposure to reactive oxygen species
coincident with exposure to DNA adduct-forming platinum-
based chemotherapies can be the death knell for cancer cells.
Iida et al. found that the gut microbiota influence the expression
of several enzymes that myeloid cells require to make reactiveoxygen species in the tumor microenvironment. These reactive
oxygen species were important for optimal response to specific
chemotherapies. In mice, the microbiota’s influence on the
immune system appears important not only for homeostatic
regulation but also for response to cancer therapy. In a second
study, Zitvogel and colleagues identified a gut microbe-depen-
dent mechanism by which cyclophosphamide, a chemotherapy
used to treat many non-CRCs, injures the small intestine and
triggers anti-tumor Th1 and Th17 immune responses (Viaud
et al., 2013).
While the studies of Iida et al. and Viaud et al. are of great
interest, there are numerous limitations that need to be consid-
ered for the translation of such findings to humans. Anatomical,
behavioral, and dietary differences, which distinguish mice
from humans, influence luminal and mucosal intestinal microbial
communities, their transcriptomes, and their metabolomes.
Thus, beyond identifying clades that track with chemotherapy
responses, subsequent studies need to address how microbial
pattern recognition receptor and metabolite signaling in the
host, specifically human hosts, can be tuned to both mitigate
side effects and optimize tumor responsiveness to chemother-
apies. This point requires special consideration as cancer
patients often require antibiotics for bacterial infections while
receiving chemotherapy. An overarching message of the above
studies is that we need to develop awell-nuanced understanding
of how drug and biologic treatments alter the gut microbiota
and immune system function.
Conclusion
Cancer has been called the ‘‘emperor of all maladies’’ (Mukher-
jee, 2010), and in unraveling the role of the microbiota in colo-
rectal carcinogenesis, research efforts are giving this emperor
new clothes and laying him bare. With sufficient research
support, the vast genomic and metabolic potential of the gut
microbiota may be realized as the most powerful weapon in
the 40-plus year war on cancer. Specific species, microbial
consortia, and microbial metabolites generated from ingested
foodstuffs are all potential targets for decreasing or increasing
cancer risk and perhaps even for diagnosis, treatment stratifi-
cation, and therapy.
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